What are the indications for N‑acetylcysteine (NAC) in liver injury?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Indications for N-Acetylcysteine (NAC) in Liver Injury

NAC is strongly indicated for acetaminophen-induced liver injury and acute liver failure, and should also be administered in non-acetaminophen acute liver failure, particularly in early-stage hepatic encephalopathy.

Primary Indication: Acetaminophen-Induced Liver Injury

NAC is the definitive antidote for acetaminophen overdose to prevent or lessen hepatic injury 1. The FDA explicitly approves NAC for both acute ingestion and repeated supratherapeutic ingestion (RSI) of acetaminophen.

Treatment Algorithm for Acetaminophen Toxicity:

  • Timing is critical: Maximum efficacy occurs when NAC is initiated within 0-8 hours post-ingestion 1
  • Efficacy diminishes progressively after 8 hours, but treatment between 15-24 hours still provides limited benefit and should not be withheld 1
  • Mortality benefit is time-dependent:
    • <10 hours: 2.9-6.1% severe hepatotoxicity, no deaths 2
    • 10 hours: 26.4% severe hepatotoxicity 2

    • Treatment delay >16 hours: 62% severe hepatotoxicity 2

When to Initiate NAC for Acetaminophen:

  1. If time of ingestion is unknown: Start NAC immediately, then obtain acetaminophen level 1
  2. If acetaminophen level unavailable within 8 hours OR clinical evidence of toxicity: Start NAC immediately 1
  3. If patient presents >8 hours post-ingestion: Start NAC immediately regardless of level 1
  4. If <8 hours post-ingestion with known level: Use Rumack-Matthew nomogram to guide treatment 1

Level B Recommendation: Administer NAC to patients with hepatic failure thought to be due to acetaminophen 2.

Level C Recommendation: Administer NAC to patients with hepatotoxicity from suspected acetaminophen overdose, including repeated supratherapeutic ingestions 2.

Secondary Indication: Non-Acetaminophen Acute Liver Failure

The AGA recommends NAC use in non-acetaminophen ALF only within clinical trials (no formal recommendation), though emerging evidence supports broader use 3.

Evidence Supporting Use in Non-Acetaminophen ALF:

The most recent high-quality meta-analysis (2021) demonstrates significant benefits 4:

  • Overall survival improved: OR 1.77 (95% CI 1.3-2.41) 4
  • Transplant-free survival improved: OR 2.85 (95% CI 2.11-3.85) 4
  • Post-transplant survival improved: OR 2.44 (95% CI 1.11-5.37) 4
  • Shorter hospital stay: Mean difference 7.79 days (95% CI 6.93-8.66) 4

Specific Patient Populations Benefiting Most:

NAC shows particular benefit in patients with early-stage (Grade 1-2) hepatic encephalopathy 3. In post-hoc analysis, mortality benefit was identified specifically in these early encephalopathy stages, suggesting NAC should be prioritized when patients present before advanced hepatic failure develops.

Clinical Decision-Making for Non-Acetaminophen ALF:

Consider NAC in the following scenarios:

  • ALF of indeterminate cause (may be occult acetaminophen) 3
  • Drug-induced liver injury from non-acetaminophen agents 5, 6
  • Viral hepatitis causing ALF 7, 8
  • Early hepatic encephalopathy (Grade 1-2) 3

Important Caveats and Pitfalls

Safety Profile:

NAC demonstrates acceptable safety across all indications 5, 6:

  • IV route: Most common adverse events are anaphylactic reactions and cutaneous reactions 9
  • Oral route: Most common adverse events are gastrointestinal symptoms 9
  • Overall: Relatively minor toxicity compared to potential mortality benefit 3

Common Pitfalls to Avoid:

  1. Don't delay treatment waiting for acetaminophen levels if ingestion time is unknown or >8 hours 1
  2. Don't withhold NAC after 24 hours - while efficacy is limited, it doesn't worsen outcomes and reported ingestion times may be inaccurate 1
  3. Don't rely solely on patient-reported quantity ingested - this is often inaccurate 1
  4. Don't assume normal transaminases in ED exclude toxicity - levels may rise over subsequent hours 2

Evidence Limitations:

While the 2017 AGA guideline states NAC should only be used in non-acetaminophen ALF within clinical trials 3, subsequent meta-analyses from 2021 and 2022 demonstrate consistent mortality benefit 4, 5. The guideline's conservative stance reflects the "very low quality of evidence" available at that time, but more recent systematic reviews with larger patient populations support broader use.

In real-world practice, given NAC's favorable safety profile and demonstrated mortality benefit in recent meta-analyses, withholding NAC in non-acetaminophen ALF—particularly with early encephalopathy—represents a missed opportunity to improve transplant-free survival.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.